EASL: The European Association for the Study of the Liver

Hepatitis B elimination requires expanded vaccination, screening, treatment, and education, Helen Nde, MPH, said.

Early findings from the CDAF-Relink program highlight gaps in re-engagement, outreach barriers, and opportunities to reconnect patients to care.

Hepatitis B re-engagement efforts are underreported in lower-resource settings, highlighting gaps in care and the need for greater action.

Phase 2 data show promising antiviral activity with tobevibart plus elebsiran in hepatitis D, supporting further evaluation in the phase 3 ECLIPSE program.

The shift toward fibrosis end points and noninvasive biomarkers in MASH trials may ease enrollment, improve assessment, and reduce biopsy use, Zobair M. Younossi, MD, said.

Tarik Asselah, MD, PhD, explains why HDV RNA suppression deepened through 2 years with tobevibart plus elebsiran.

Naim Alkhouri, MD, discusses real-world resmetirom data in MASH, GLP-1 combinations, and using ANTICIPATE-NASH in practice.

Re-engagement strategies for hepatitis B show promise in the US, but data gaps and structural barriers are slowing progress toward WHO elimination targets.

Late-breaker data from EASL Congress 2026 mark a pivotal moment in chronic hepatitis B research.

MASH cirrhosis treatment, fibrosis reversal, and population screening were cited by experts as hepatology's biggest gaps.

Resmetirom boosts MASH cardiovascular protection, lowering LDL cholesterol and Lp(a) even on statins, and pushes routine Lp(a) testing.

New data showed durable hepatitis D virus RNA suppression through 96 weeks with tobevibart plus elebsiran, while higher BMI appeared to affect ALT normalization.

Two posters presented at EASL 2026 clarify where peginterferon alfa-2b fits in therapy for patients with chronic hepatitis B.

Heiner Wedemeyer, MD, offered an unflinching assessment of viral hepatitis medicine, celebrating landmark breakthroughs while issuing a clear warning that the field is failing the populations it set out to protect.

Week 96 SOLSTICE data show tobevibart plus elebsiran deepens durable hepatitis D virus (HDV) and HBsAg suppression, beating monotherapy.

Elliot Tapper, MD, explains how digital health, precise screening, and direct hepatology care can treat alcohol-associated liver disease and mental health.

Re-engagement rates for patients with hepatitis B lost to follow-up range from 2% to 100% globally, with proximity to patients driving the best outcomes.

Low risk stratification rates are fueling a looming MASH cost crisis, but earlier treatment access could bend the curve, said Zobair M. Younossi, MD.

New data highlight pevifoscorvir’s potent antiviral activity and sustained hepatitis B antigen suppression lasting up to 96 weeks after treatment.

Meena Bansal, MD, discusses the evolving MASH pipeline and why precision phenotyping, biomarkers, and cardiovascular outcomes data remain critical gaps.

Phase 2 data for DD01 and pemvidutide show liver-directed MASH benefits beyond weight loss, with strong tolerability heading into phase 3.

Full results from the pivotal B-Well 1 and B-Well 2 phase 3 trials confirm that bepirovirsen delivers statistically significant functional cure rates in chronic hepatitis B.

Two posters presented at the EASL Congress 2026 highlight promising clinical and preclinical findings for AHB-137.